Clinical studyFactors predicting development of renal involvement in progressive systemic sclerosis☆
References (28)
- et al.
Resolution of renal failure with malignant hypertension in scleroderma. Case report and review of the literature
Am J Med
(1979) - et al.
Classification and nomenclature of progressive systemic sclerosis (scleroderma)
Clin Rheum Dis
(1979) - et al.
The management of renal scleroderma. Experience with dialysis, nephrectomy and transplantation
Am J Med
(1978) - et al.
Renal involvement in progressive systemic sclerosis (generalized scleroderma)
Am J Med
(1957) - et al.
Pericardial disease in scleroderma (systemic sclerosis)
Am J Med
(1974) Progressive systemic sclerosis (scleroderma)
- et al.
Response of patients with renal involvement by progressive systemic sclerosis to antihypertensive therapy
Clin Sci
(1981) - et al.
Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects
J Clin Endocrinol Metab
(1969) - et al.
Qualitative testing for circulating immune complexes by use of zone electrophoresis on agarose
Clin Chem
(1980) - et al.
D-penicillamine therapy in progressive systemic sclerosis (scleroderma). A retrospective analysis
Ann Intern Med
(1982)
The natural history of skin involvement in progressive systemic sclerosis (PSS)
Arthritis Rheum
Preliminary criteria for the classification of systemic sclerosis (scleroderma)
Arthritis Rheum
Clinical comparison of two variants of progressive systemic sclerosis (PSS): diffuse scleroderma and CREST syndrome
Arthritis Rheum
Control of hypertension and reversal of renal failure in scleroderma
N Engl J Med
Cited by (228)
Pulmonary Hypertension in Scleroderma– Evaluation and Management
2023, Disease-a-MonthCitation Excerpt :SRC is seen in up to 10% of SSc patients and is exclusively found in DcSSc, and usually is seen within 3 years of diagnosis.44 SRC can manifest with acute onset of moderate-to-severe ‘accelerated’ hypertension and also oliguric renal failure.44,45 Hyperreninemia, microangiopathy, MAHA, and congestive heart failure are the common features seen with SRC, rarely do patients also exhibit hypertensive encephalopathy and retinopathy.45
Renal involvement in systemic sclerosis
2023, Autoimmunity ReviewsTraining the Next Generation of Rheumatologists: What Is the Best Way to Teach Fellows About Scleroderma?
2023, Rheumatic Disease Clinics of North AmericaScleroderma hypertensive renal crisis among systemic sclerosis patients: A national emergency department database study
2022, American Journal of Emergency MedicineCitation Excerpt :This could be secondary to improved and timely management especially the use of angiotensin-converting enzyme inhibitor use over the last few decades, as has been reported previously [19,20]. Several factors that could predict the occurrence of SRC in SSc patients were studied, and they include recent use of corticosteroids at more than 15 mg/day in the last six months, new anemia, diffuse and rapidly progressive skin thickening, large joint contractures, new cardiac events such as pericardial effusion or congestive heart failure, and cyclosporin therapy [21]. Our study has also shown that the history of CHF was a significant positive predictor for the development of SRC among SSc patients.
Updates in Systemic Sclerosis Treatment and Applicability to Pediatric Scleroderma
2021, Rheumatic Disease Clinics of North AmericaReview for best practice in clinical rheumatology juvenile systemic sclerosis – Updates and practice points
2021, Best Practice and Research: Clinical Rheumatology
- ☆
This work was supported by grants from the National Institutes of Health (AM-21393 and FR-00056), the RGK Foundation, Austin, Texas, and the Arthritis Foundation, Western Pennsylvania Chapter.
- 1
From the Divisions of Rheumatology and Clinical Immunology and of Clinical Pharmacology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.